YOLFTbeta
Bcal Diagnostics Ltd

Bcal Diagnostics Ltd

BDX · AU · Healthcare / Diagnostics & Research

0.06AUD-0.00 (-1.64%)

Price History

Full chart

Market Stats

Previous Close0.061
Open0.062
Day Range0.06 – 0.065
52-Week Range0.052 – 0.155
Volume17.21K
Market Cap32.08M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.02
Dividend Yield0.00%
Beta0.81
50-Day Avg0.0695
200-Day Avg0.0882

About

BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMs. Anne-Louise Arnett
  • Employees0
  • Headquarters50 Clarence Street, Sydney, NSW, Australia, 2000, Australia
  • Websitehttps://www.bcaldiagnostics.com

Leadership

  • Ms. Jayne Andrea ShawCo-Founder & Executive Chairman
  • Ms. Anne-Louise ArnettChief Executive Officer
  • Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICDCFO & Company Secretary · b. 1953
  • Mr. Sean Alexander KennedyDirector of Corporate Finance

Financials

Income Statement

Currency: AUD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue242.29K258.24K442.10K275.25K718.67K2.79M3.10M21.64K182.51K
Growth (%)-+6.59%+71.19%-37.74%+161.09%+288.29%+11.02%-99.30%+743.51%
Cost of Revenue14.04K3.55K7.73K-20.61K113.61K579.79K-717.23K
Gross Profit228.25K254.69K434.37K275.25K698.06K2.79M3.10M21.64K-534.72K
Gross Margin94.21%98.62%98.25%100.00%97.13%100.00%100.00%100.00%-292.98%
Operating Expense932.54K937.79K1.57M2.08M3.73M7.46M8.55M9.98M8.86M
Operating Income-704.29K-683.10K-1.14M-1.80M-3.03M-4.67M-5.45M-9.96M-9.39M
Operating Margin-290.68%-264.52%-257.51%-654.03%-421.26%-167.48%-175.82%-46043.03%-5145.88%
EBITDA-690.25K-677.84K-1.03M-1.80M-4.06M-7.72M-5.67M-6.19M-8.67M
EBITDA Margin-284.89%-262.48%-233.12%-653.94%-565.62%-276.74%-182.91%-28623.89%-4752.90%
Net Income-467.63K-429.96K-696.36K-1.52M-3.39M-5.06M-6.40M-7.24M-7.37M
Net Income Margin-193.01%-166.49%-157.51%-554.03%-471.08%-181.39%-206.58%-33465.98%-4038.97%
R&D251.90K205.38K466.77K664.11K1.91M4.47M4.36M1.57M4.67M
R&D as % of Total Revenue103.97%79.53%105.58%241.27%266.30%160.36%140.77%7261.51%2560.16%
Interest Expense5.63K5.10K00016.04K99.93K92.03K346.64K
Interest Expense % of Total Revenue2.32%1.97%0.00%0.00%0.00%0.57%3.23%425.32%189.93%

Balance Sheet

Currency: AUD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets560.02K540.34K819.55K4.13M10.59M8.37M12.27M9.91M7.66M
Total Liabilities641.86K52.14K380.64K525.60K950.42K3.16M3.68M3.69M8.49M
Total Equity-81.85K488.20K438.92K3.61M9.64M5.21M8.59M6.22M-826.19K
Cash309.13K276.64K416.23K3.41M5.57M3.17M6.47M4.52M1.59M
Total Debt500.00K-300.00K--1.06M1.52M2.38M6.92M
Net Debt190.87K-276.64K-116.22K-3.41M-5.57M-2.11M-4.95M-2.14M5.33M

Cash Flow

Currency: AUD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-470.81K-525.01K-661.65K-1.21M-3.22M-6.05M-4.52M-6.14M-6.16M
Investing Cash Flow-14.12K-7.47K-3.81K-3.85K-4.03M3.64M-1.15M-787.67K-1.44M
Financing Cash Flow500.00K500.00K805.04K4.20M9.41M13.24K8.97M4.97M4.66M
Capital Expenditure14.03K7.47K3.81K3.85K4.03M362.47K1.15M787.67K458.99K
Free Cash Flow-484.84K-532.48K-665.46K-1.21M-7.25M-6.41M-5.67M-6.92M-6.62M
FCF to OCF102.98%101.42%100.58%100.32%225.05%105.99%125.45%112.84%107.45%

Earnings

Report DateJul 19, 2021Feb 17, 2022Aug 29, 2022Feb 23, 2023Feb 27, 2025Aug 28, 2025
EPS Estimate0.000.000.000.000.000.00
EPS Actual-0.01-0.01-0.01-0.01-0.01-0.01
Surprise------
Timing------

Key Statistics & Ratios

Market Cap32.08M
Enterprise Value36.67M
Trailing P/E0.00
Forward P/E0.00
Price / Sales13.64
Price / Book10.18
EPS-0.02
Book Value-0.002
Revenue (TTM)2.35M
Gross Profit (TTM)2.35M
EBITDA-6.59M
Profit Margin0.00%
Operating Margin-313.41%
Return on Equity-273.29%
Return on Assets-50.29%
Shares Outstanding368.68M
Shares Float179.11M
Beta0.81
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%